Home-based SCIg


Intravenous literature: Woodall, A. and Jones, S. (2010) Switching to home-based SCIg for Multifocal motor neuropathy (MMN). British Journal of Nursing 19(5), Supp: S27 – S31.


Multifocal motor neuropathy (MMN) is an immune-mediated disorder with slowly progressive asymmetric weakness of the limbs that can lead to significant disability. The recommended treatment is intravenous immunoglobulin (IVIg) which is often administered in a hospital setting. When self-administered in the home setting both subcutaneously administered immunoglobulin (SCIg) and IVIg provide patients with greater autonomy. The Department of Health’s National Service Framework for long-term neurological conditions promotes supported self-care and self-management for patients living with a chronic disease. This paper reports the objective assessment of three adults with MMN who, supported and trained by two specialist nurses, were switched from IVIg to 16% SCIg self-administered at home. Reasons for switching to SCIg included inconvenience of IVIg treatment (2 patients) and pulmonary embolus after IVIg (1 patient). Grip strength, time to complete a 9-hole peg test in the left/right hands (2 patients), and duration of right heel raise (1 patient) were assessed pre-SCIg and during ongoing maintenance treatment (range: 160-200 mL SCIg/week). With regular assessment of patients’ responses, the SCIg dose was adjusted, when required, to maintain the patients’ normal performance. SCIg self-administered at home was an effective alternative to IVIg in these patients.


Comments are closed.

Free Email Updates
Join 5.5K IVTEAM members. Subscribe now and be the first to receive all the latest free updates from IVTEAM!
100% Privacy. We don't spam.